Solara Active Pharma Sciences: Inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the…
Solara Active Pharma Sciences (SOLARA) filed a disclosure titled "Inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter". The company is valued at about ₹3,564 crore.
What happened
Solara Active Pharma Sciences (SOLARA) filed a disclosure with the exchanges on 16 October 2026 at 01:38 PM titled "Inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter".
Company snapshot
Solara Active Pharma Sciences is a small-cap company, with a market value of about ₹3,564 crore.
The stock last traded at ₹738.7, against a 52-week range of ₹422–₹774 (4.6% below the high).
Before this filing the shares had moved −9.4% over the month and +13.7% over three months. Average daily turnover over the last 20 sessions was about ₹20.07 crore.
Promoters held 41.93% at the end of Q1 FY27, down 0.07% points from the previous quarter; 37.11% of promoter shares were pledged. Foreign institutions owned 11.52% and domestic institutions 3.74%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 319 | 10.5 | 2.46 |
| Q2 FY26 | 314 | -10.1 | -2.36 |
| Q3 FY26 | 349 | -17.4 | -3.98 |
| Q4 FY26 | 387 | 9.6 | 2.2 |
| Q1 FY27 | 382 | 16.3 | 3.52 |
What history shows
This is not the company's first board meeting disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 0.3% on average the next trading day and was down 14.9% on average after five days (2 filings with price data).
Market-wide, 2,897 board meeting filings with an impact score of 50 or more saw an average next-day move of −0.0%, with 43% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 9 Oct 2026 | Solara Active Pharma Sciences Ltdhas informed BSE that the meeting… | +1.9% | — |
| 16 Jul 2026 | Board Meeting Intimation for Intimation Regarding Board Meeting… | −1.4% | −14.9% |
What to watch
- 16 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Solara Active Pharma Sciences ESG Rating Upgrade FY26
- Solara Active Pharma to host analyst call on Oct 16 for Q2FY27 results
- Solara Pharma approves forfeiture notice for unpaid rights shares
- Solara Active Pharma (NSE:SOLARA) Q2 FY27 Depository Certificate Filed
- Solara Active Pharma Sciences Ltd Reports ₹28.46 Crore Consolidated Profit In Q2
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.